Information Security Architect - Encryption Agility Team
Amgen
Information Security Architect - Encryption Agility Team
Amgen
Makes biotech medicines for serious illnesses
Role Name: Principal Information Security Architect - Encryption Agility Team
Job Posting Title: Senior Specialist Information Security - Encryption Agility Team Architect
Workday Job Title: Senior Specialist Information Security
Department Name: Trusted Core Technologies
Role GCF: 6A
ABOUT AMGEN
Amgen harnesses the best of biology and technology to fight the world's toughest diseases, and make people's lives easier, fuller and longer. We discover, develop, manufacture and deliver innovative medicines to help millions of patients. Amgen helped establish the biotechnology industry more than 40 years ago and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today.
ABOUT THE ROLE
Role Description:
The Senior Specialist Information Security - Encryption Agility Team Architect will serve as the Principal Architect for Amgen's enterprise Encryption Agility Service for Post-Quantum Cryptography (PQC) Readiness Preparation. This role is the senior technical authority for enterprise encryption, cryptography, crypto agility, and post-quantum cryptography architecture across Amgen. The role partners with the Senior Manager Information Security - Encryption Agility Service Lead to translate Amgen's post-quantum roadmap into governed standards, reference architectures, implementation patterns, discovery requirements, remediation patterns, test plans, and production rollout guidance. The role is expected to be deeply technical and hands-on, while also able to influence enterprise architecture, application, cloud, infrastructure, identity, Public Key Infrastructure (PKI), Key Management Services (KMS), certificate management, Digital Identity Access Services (DIAS), Operational Technology (OT), and third-party stakeholders.
The architect will define what good looks like for Amgen's 2030 quantum-ready target state and work backward to establish the architecture, tooling, policies, and patterns needed to get there. The role will create practical architecture for the Cryptographic Bill of Materials (CBOM), cryptographic discovery, Certificate Lifecycle Management (CLM), key and secret management, algorithm transition, Steal-Now-Decrypt-Later (SNDL) mitigation, Post-Quantum Public Key Infrastructure (PQ-PKI), hybrid Transport Layer Security (TLS), approved cryptographic libraries, and compensating controls for legacy or unchangeable applications. The individual must be comfortable reviewing source code findings, certificate chains, cipher suite data, cloud key configurations, secrets management patterns, tool integrations, and vendor cryptographic evidence.
This role does not replace teams that already own infrastructure, PKI/certificates, applications, identity, cloud, or OT. Instead, it sets the architecture and technical standards for how encryption and cryptography must be used, discovered, measured, modernized, and governed across those domains, and coordinates with service owners to make the PQC transition practical, measurable, and controlled in a global, regulated environment.
Roles & Responsibilities:
Basic Qualifications and Experience:
Functional Skills:
Must-Have Skills:
Good-to-Have Skills:
Professional Certifications:
Soft Skills:
EQUAL OPPORTUNITY STATEMENT
Amgen is an Equal Opportunity employer and will consider you without regard to your race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, or disability status.
We will ensure that individuals with disabilities are provided with reasonable accommodation to participate in the job application or interview process, to perform essential job functions, and to receive other benefits and privileges of employment. Please contact us to request an accommodation.
.Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.
Explore more opportunities at Amgen